Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-HDS
- Development stage
- Unknown
- Lead developer
- Gruppo Italiano Terapie Innovative nei Linfomi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
R-HDS (Rituximab-supplemented High-Dose Sequential chemotherapy) is an intensive chemo-immunotherapy regimen developed by the Gruppo Italiano Terapie Innovative nei Linfomi (GITIL) for the treatment of high-risk, previously untreated diffuse large B-cell lymphoma (DLBCL). The protocol integrates the anti-CD20 monoclonal antibody rituximab with a sequential high-dose chemotherapy schedule including cyclophosphamide, cytarabine (Ara-C), etoposide, cisplatin, mitoxantrone, and melphalan. This intensive approach is followed by autologous peripheral blood progenitor cell (PBPC) transplantation to rescue hematopoiesis. The regimen aims to overcome poor prognostic factors in patients with high age-adjusted International Prognostic Index (aaIPI) scores by maximizing dose intensity and utilizing the synergistic effects of targeted immunotherapy and multi-agent cytotoxic chemotherapy.
- Other names
- Rituximab-HDSRituximab-supplemented High-Dose Sequential chemotherapyGITIL R-HDS
02
Targets
Beyond the preview
Go deeper on R-HDS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-HDS.